A, B, E, F, & G. There is currently no recommended screen for endometrial cancer, but knowing the risk factors is important for counseling patients. Endometrial cancer is associated with obesity, hyperinsulinemia, and chronic anovulation, which are all characteristics of polycystic ovary syndrome (SOR B). Obesity leads to higher estrogen levels, increasing the risk for endometrial cancer; physical activity has been shown to reduce the risk of endometrial cancer (SOR A). Estrogen levels are lower in women who are breastfeeding, and having decreased levels of estrogen for extended periods of time is associated with a lower risk of endometrial cancer (SOR B). As longer exposure to estrogen increases the risk of endometrial cancer, the combination of early menarche and nulliparity increases the risk because of uninterrupted high estrogen levels (SOR B). Oral contraceptives have been found to reduce the risk of endometrial cancer. The protective effect increases with the length of time they are used, and benefits can last years after a woman has stopped taking them (SOR A). Although raloxifene has estrogen-like effects on the uterus, it has not been shown to increase the risk of endometrial cancer (SOR A). Tamoxifen is a selective estrogen receptor modulator that has estrogen-like effects. While it has a protective effect on breast tissue, its effect on the uterus increases the risk of endometrial cancer (SOR A). Hereditary nonpolyposis colon cancer is an inherited disorder linked to certain genes. Women with this cancer have a much higher risk of developing endometrial cancer (SOR B). More test answers on https://studyhippo.com/abfm-preventive-medicine/